Monotherapy with ivosidenib has been approved for the treatment of newly diagnosed IDH1+ relapsed/refractory AML patients not eligible for standard chemotherapy due to the results obtained by two studies [113,114]. The gene discussed is IDH1; the disease is acute myeloid leukemia.